CBUS

Cibus, Inc. (CBUS) - Q2 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2024. Cibus, Inc. is an agricultural biotechnology company utilizing gene editing (RTDS platform) to develop plant traits for productivity and sustainable ingredients. The company operates in an "Up-C" structure, consolidating Cibus Global, LLC. The reporting period reflects a full quarter of combined operations following the May 2023 merger with Cibus Global.

Key Financial Metrics

Note: Q2 2023 data is not directly comparable as it includes only one month of combined Cibus operations and five months of Legacy Calyxt operations.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 325% in Q2 2024 and 479% for the six months ended June 30, 2024, compared to the prior year periods. This growth is driven by the inclusion of Cibus Global revenue, specifically from collaboration agreements for Rice and Soybean research.
• Expense Increases: Research and Development (R&D) expenses rose 54% in Q2 and 135% for the six months, primarily due to the acquisition of Cibus Global (increased headcount, facility costs, and stock-based compensation). Selling, General, and Administrative (SG&A) expenses decreased 16% in Q2 but increased 22% for the six months, influenced by one-time merger costs in the prior year period.
• Royalty Liability Impact: Royalty liability interest expense surged 234% in Q2 and 553% for the six months to $8.7 million and $17.1 million respectively, resulting from the assumption of the liability in the merger.
• Capital Raises: The company raised approximately $28.5 million in net proceeds during the first half of 2024 through a Registered Direct Offering ($12.0 million) and its ATM Facility ($16.5 million).

Guidance, Outlook, and Risks

• Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for at least one year from the filing date. The company expects existing cash ($30.0 million) to fund operations only into the fourth quarter of 2024 without additional financing.
• Capital Needs: The company explicitly states it will need to raise additional capital to support business plans. Failure to do so may result in significant cost reductions, delays, or cessation of operations.
• Operational Milestones: Progress includes the "shipping" of the Pod Shatter Reduction (PSR) trait in Canola, advancements in Herbicide Tolerance (HT) traits for Rice, and the addition of a Nutrient Use Efficiency (NUE) trait to the portfolio. A scalable gene editing process in Wheat was established in Q1 2024.
• Regulatory Environment: The company highlights a favorable shift in global regulations, with Canada and the EU moving toward treating gene-edited traits similarly to conventional breeding, which could accelerate commercialization.
• Unusual Items: Non-operating income included a $1.2 million gain from the fair value adjustment of Common Warrants in Q2 2024.

Investor Verification Checklist

• Cash Runway: Verify the timeline for the next capital raise given the "substantial doubt" disclosure and the projection that current cash lasts only into Q4 2024.
• Royalty Liability Terms: Review the Warrant Exchange Agreement details regarding the 10% royalty on "Subject Revenues" and the $50 million revenue threshold before payments commence.
• Commercialization Timeline: Assess the specific milestones and expected revenue recognition dates for the PSR (Canola) and HT (Rice) traits currently in development or "shipping."
• Dilution Risk: Monitor the utilization of the $80 million ATM facility and the terms of the 2024 Common Warrants (exercise price $10.00) for potential future dilution.
• Lease Obligations: Note the extension of the San Diego headquarters lease until March 2033, adding $16.4 million in operating lease liabilities.